Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Immunotech Biopharm's Enterprise Value is HK$1,877.34 Mil.
Immunotech Biopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-357.62 Mil. Therefore, Immunotech Biopharm's EV-to-EBIT ratio for today is -5.25.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Immunotech Biopharm's Enterprise Value is HK$1,877.34 Mil.
Immunotech Biopharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-357.62 Mil. Therefore, Immunotech Biopharm's EV-to-EBITDA ratio for today is -5.25.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Immunotech Biopharm's Enterprise Value is HK$1,877.34 Mil.
Immunotech Biopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00 Mil. Therefore, Immunotech Biopharm's EV-to-Revenue ratio for today is .
Immunotech Biopharm Enterprise Value Historical Data
The historical data trend for Immunotech Biopharm's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Immunotech Biopharm's Enterprise Value
For the Biotechnology subindustry, Immunotech Biopharm's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunotech Biopharm's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Immunotech Biopharm's Enterprise Value falls into.
Immunotech Biopharm Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Immunotech Biopharm's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunotech Biopharm (HKSE:06978) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Immunotech Biopharm's current Enterprise Value is HK$1,877.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Immunotech Biopharm's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-357.62 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Immunotech Biopharm's current Enterprise Value is HK$1,877.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Immunotech Biopharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-357.62 Mil.
Immunotech Biopharm's current Enterprise Value is HK$1,877.34 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Immunotech Biopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunotech Biopharm Enterprise Value Related Terms
Thank you for viewing the detailed overview of Immunotech Biopharm's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Immunotech Biopharm (HKSE:06978) Business Description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06978 has been successfully added to your 